Abstract
To date, it remains unclear whether serum levels of the neuron-specific enolase (NSE) andthe S-100 protein definitely correspond tothe severity and possible outcomes of hypoxicischemic encephalopathy (HIE), as well as their predictable values regarding to thepotential development of such an unfavorableresult of HIEtreatment as cerebralleukomalacia.Objective to evaluatethe dynamics of such serum biomarkersas neuron-specific enolase(NSE) and protein S-100 in full-term newborns during the acute period of HIE and findout their possible correlation with the development of cerebral leukomalacia.Materials and methods. A prospective, single-center cohort study was performed in 205full-term infants,weretreated in the neonatal intensive care unit due to hypoxic-ischemicencephalopathy in 2012-2017.All the babieswere stratifiedby the diagnosis of cerebralleukomalacia, which complicated the treatment of moderate to severe neonatal hypoxicischemic encephalopathy. Serum concentrations of neuron-specific enolase (NSE) andprotein S-100 were determined on 1st, 3rd and 5th days of treatment both in total cohortand in subgroups with and without development of leukomalacia.Results. Serum concentrations of both biomarkers significantly exceeded the normalvalues in whole cohort during all days of the research, but the dynamics of their declinediffered from each other. Basingon multivariate analysis of variance ANOVA, a significantcorrelation of the S-100 protein level on the 1st day of treatment with the possibledevelopment of cerebral leukomalacia was determined (p=0.024), but we did not revealed the same to the neuron-specific enolase (p=0.656), despite its dynamicssignificantly changed at all stages of the study.Conclusions. Evaluationfor serum concentrations of such biomarkers of brain damage asprotein S-100 and neuron-specific enolase in the acute period of hypoxic-ischemicencephalopathy in full-term newborns has a significant diagnostic and prognostic valueand correlates with the severity and outcomes of HIE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
